Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 28 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following upcoming investor conferences in March:

• Cowen 43rd Annual Health Care ConferenceFireside Chat: Monday, March 6, 2023, at 1:30 p.m. ET

• Oppenheimer 33rd Annual Healthcare Conference Presentation: Tuesday, March 14, 2023, at 8:00 a.m. ET

• Barclays Global Healthcare Conference Fireside Chat: Wednesday, March 15, 2023, at 3:35 p.m. ET

• Jefferies Biotech on the Bay Summit1x1 and small group meetings: Thursday, March 16, 2023

The presentations will be webcast live and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentations will be made available for a limited time.

##

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT: 

Immunocore Sébastien Desprez, Head of CommunicationsT: +44 (0) 7458030732E: [email protected]Follow on Twitter: @Immunocore Consilium Strategic Communications (corporate and financial)Mary-Jane Elliott/ Chris Welsh/Jessica HodgsonT: +44 (0)203 709 5700E: [email protected]

Investor Relations  Clayton Robertson, Head of Investor RelationsT: +1 215-384-4781E: [email protected]

Source: Immunocore Holdings Limited

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Steelworkers back Canada holding the line on trade, call for a stronger response to protect Canadian jobs and industry
• New Meme Coins for Late August: $BULLSKI Leads the Fresh Entries
• TD Cowen Assumes Immunocore Holdings (IMCR) at Buy